Board of Directors
Robert B. Cameron, M.D.
UCLA Medical School
Nicholas J. Vogelzang, M.D.
Nevada Cancer Institute
M. Ann Abbe
Arlington, Texas
Michael Harbut, M.D., M.P.H.
Royal Oak, Michigan
Roger G. Worthington, Esq.
Dallas, Texas
Mathew Bergman, Esq.
Seattle, Washington
Susan Vento
St. Paul, Minnesota
Mouzetta Zumwalt-Weathers
Cary, North Carolina
Ulf Jungnelius, M.D.
Pfizer, Inc.
In Memoriam
Congressman Bruce F. Vento
Science Advisory Board
Harvey Pass, M.D., Chairman
Karmanos Cancer Institute
Victor Roggli, M.D.
Duke University
Robert N. Taub, M.D.
Columbia University
Lary A. Robinson, M.D.
H. Lee Moffit Cancer Center
Steve Hahn, M.D.
University of Pennsylvania
Joseph R. Testa, Ph.D.
Fox Chase Cancer Center
Claire Verschraegen, M.D.
University of New Mexico
Eric Vallieres, M.D.
Swedish Cancer Institute
Dan Miller, M.D.
Emory University
Raphael Bueno, M.D.
Harvard/Brigham and Women's
Hedy Lee Kindler, M.D.
University of Chicago
W. Roy Smythe, M.D.
Texas A&M
Executive Director
Christopher E. Hahn
MARF, inc.
1609 Garden Street
Santa Barbara, CA 93101
tel (805) 560-8942
fax (805) 560-8962
c-hahn@marf.org
http://www.marf.org
|
September 8, 2004
MARF-Funded Mesothelioma Research,
2000-2004
MARF's research program is designed to
spur and develop more of the experimental research which can
lead to breakthroughs similar to Alimta, the first drug
specifically approved by the FDA for mesothelioma. Selection
of the projects for funding is based on the prestigious
National Cancer Institute peer review model, where scientific
experts in the particular field evaluate the proposed
projects on their merits, and the best projects are the ones
which get funded. This is the only independent, peer-reviewed
mesothelioma research funding program in the U.S.
MARF has now awarded over $1.3 million in
mesothelioma research funding to exceptional projects. Its
track record of consistent support for high quality
mesothelioma treatment research is now stimulating more and
higher quality mesothelioma research. In its first funding
cycle in 2000, MARF received seven grant applications and
awarded two grants. Last year MARF received 25 applications
from highly regarded centers in the U.S., including Harvard,
Duke, Sloan Kettering and Vanderbilt, and six other
countries, and awarded grants to five stellar projects. For
2004, MARF has now received 31 grant applications.
2000
Identification of a 1p22 Tumor
Suppressor Locus Frequently Deleted in Malignant
Mesothelioma
Joseph R. Testa, Ph.D.
Director, Human Genetics Program
Fox Chase Cancer Center
Biologic Markers of Angiogenesis in
Malignant Mesothelioma
Hedy Kindler, MD
Assistant Professor of Medicine, Hematology/Oncology
University of Chicago
Validation of Prognostic Markers in
Mesothelioma
Raphael Bueno, M.D.
Assistant Professor of Surgery
Division of Thoracic Surgery
Harvard Medical School and Brigham and Women's
Hospital
Computerized Analysis of Mesothelioma on Thoracic
Computed Tomography Scans
Samuel G. Armato III, Ph.D.
Assistant Professor
Department of Radiology
The University of Chicago
National Mesothelioma Data/Tissue Bank Pilot
Project
Dr. Robert Cameron
Chief of Thoracic Surgery
UCLA Medical School
2002
Pharmacogenetic and Pharmacogenomic Studies of
Thymidylate Synthase Enhancer Region Polymorphisms in
Mesothelioma and Their Therapeutic Implications in Patients
Treated with Pemetrexed Sodium
Muralidhar Beeram, M.D. and Johann de Bono, M.D., Ph.D.
University of Texas Cancer Therapy and Research Center
Institute for Drug Development
Molecular Diagnosis of Mesothelioma Using DNA
Methylation Signatures
Ite Laird-Offringa, Ph.D.
Assistant Professor of Surgery
USC/Norris Cancer Center
2003
Dendritic Cell-Based Immunotherapy of
Mesothelioma
Dr. B. Lambrecht, M.D., Ph.D.
Erasmus Medical Center
Rotterdam, The Netherlands
Targeted Virotherapy for Mesothelioma
David T. Curiel, M.D., Ph.D.
University of Alabama at Birmingham
Gene Therapy in Mesothelioma
Gavin J. Gordon, Ph.D.
Harvard Medical School/Brigham and Women's Hospital
Boston, MA
Radiation Sensitization Via Inhibiting Survival of
Mesothelioma and its Vascular Endothelium
Bo Lu, M.D., Ph.D.,
Vanderbilt University Medical Center
Nashville, TN
Phenotypic and Genotypic Determinants to Identify
Patients at High Risk for Mesothelioma
Jill A. Ohar, M.D.
Wake Forest University Health Sciences
Winston-Salem, NC
2004
Comparison Of Adjuvant Treatments For Mesothelioma,
Including Hyperthermia, COX-2 Inhibition, Cpil-4 Toxin
Therapy, And Standard Chemotherapy
Dr. Robert Cameron
Chief of Thoracic Surgery
UCLA Medical School
Soluble Mesothelin/MPF Related Protein (SMR) Levels
in Mesothelioma: A MARF Collaborative Study for Definition of
Biomarker Classification and Use in Therapy
Monitoring
Dr. Harvey Pass
Karmanos Cancer Institute
Mutant Epidermal Growth Factor Receptors as Targets
in Mesothelioma
Dr. Eric Vallières
Swedish Cancer Institute
|